PCM
KZR

Penserra Capital Management’s Kezar Life Sciences KZR Stock Holding History

Penserra Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-110
Closed -$9K – 1463
2021
Q3 		$9K Hold
110
– – ﹤0.01% 1370
2021
Q2 		$5K Buy
110
+4
+4% +$227 ﹤0.01% 1317
2021
Q1 		$6K Sell
106
-7
-6% -$409 ﹤0.01% 1076
2020
Q4 		$5K Buy
+113
New +$6.29K ﹤0.01% 986

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Penserra Capital Management's KZR Position: Q4 2021 in Review

Penserra Capital Management sold out of Kezar Life Sciences (KZR) in Q4 2021, closing a stake of 110 shares — an estimated $9K sold.

Penserra Capital Management first reported a position in KZR in Q4 2020 and held it in 4 quarters. The position peaked at $9K in Q3 2021. 107 funds tracked by Wall St. Rank hold KZR as of Q4 2021.

  • Penserra Capital Management reported no remaining Kezar Life Sciences position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 110 Kezar Life Sciences shares in Q4 2021, an estimated $9K.
  • Penserra Capital Management first reported a position in Kezar Life Sciences in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Kezar Life Sciences position peaked at $9K in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.